Society for Translational Oncology Fellows’ Forum (STOFF)
October 22-25, 2015
Cary, NC

This 3-day intensive forum (formerly conducted by the Cancer Education Consortium) brings together a cadre of fellows and junior faculty (within 5 years of training completion) from the leading medical oncology, surgical oncology, radiation oncology, and surgical subspecialty fellowships in the United States to educate rising stars in translational cancer research. A select number of oncology fellows from Japan and China may apply to attend this prestigious, award-winning forum as international scholars.

STOFF is now conducted under the auspices of the Society for Translational Oncology (STO) which has permanently moved the workshop to North Carolina in 2015. This will allow a unique collaboration with SAS Institute (Cary, North Carolina) whereby their experts will share their knowledge as faculty. In addition, SAS will provide meeting space to host STOFF in their Executive Briefing Center on the SAS campus.

Distinguished Faculty

STOFF faculty are researchers and educators with connections to the National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and leading US cancer centers.

Bruce A. Chabner, MD – Founder, STOFF
Chair, Education Committee, STO
Director of Clinical Research, Massachusetts General Hospital Cancer Center
Professor, Department of Medicine, Harvard Medical School

Stacey L. Berg, MD – STOFF Co-Chair
Associate Dean for Research Assurances, Baylor College of Medicine
Director, Palliative Care Program, and Director, Developmental Therapeutics Program, Texas Children’s Cancer Center
Professor, Department of Pediatrics, Baylor College of Medicine

Jeffrey A. Engelman, MD, PhD – STOFF Co-Chair
Director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center
Associate Professor of Medicine, Harvard Medical School

Keith T. Flaherty, MD – STOFF Co-Chair
Director, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital
Associate Professor, Department of Medicine, Harvard Medical School

For more information, please visit www.sto-online.org or send email to STOFF@sto-online.org
STOFF Purpose and objectives

STOFF provides an opportunity to interact with leaders in drug development and translational research. It promotes:

- Professional development
- Research, education, and the science of drug development in oncology
- Networking of oncology fellows and faculty
- Mentorship to guide career development for young oncologists

Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come.

The broad-based curriculum covers a range of topics related to new drug development. Expert faculty will lead discussions and present important information regarding preclinical and clinical evaluation including focus on validation of targets and biomarkers and confirmation of mechanism of action and resistance in clinical trials. These trials will also address racial and age-related disparities.

Renowned Alumni

Over the past 20 years, physicians who attended STOFF as Fellows and Junior Faculty have gone on to achieve significant acclaim for their clinical expertise and their exceptional research capabilities. Alumni total more than 350. A few of these distinguished alumni share their testimonial statements regarding their participation:

“**My attendance at the courses organised by Dr Bruce Chabner in 2001 when working in San Antonio have been key to my career development and continue to impact the success of my ongoing research work today.**”

– Professor Johann de Bono
Professor in Experimental Cancer Medicine and Director, Drug Development Unit
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom

“I attended the Forum, organized by Dr. Bruce Chabner in 1997. This is a wonderful course that fills a big gap in many medical oncology training programs as it covers not only the scientific aspects of pharmacology such as biological mechanisms of anticancer agents, importantly it also provides a practical perspective on how to apply such knowledge on a day-to-day basis in the care of cancer patients.”

– Dr. Lillian Siu
Director, Phase I Program and Co-Director, Robert and Maggie Bras and Family Drug Development Program, Princess Margaret Hospital
Chair, Experimental Therapeutics, Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, Canada

STO provides activities such as STOFF that help meet the educational and health needs of today’s society and future generations. Through its own mission, STO is committed to speeding the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology by:

- Bringing knowledge and strategies for critical new developments in cancer treatment to the community oncologist;
- Bridging the “translational gap” between discovery and delivery of care to the patient;
- Providing educational activities to improve physician competencies and strategies for screening, prevention, diagnosis, treatment, and management of patients with cancer.

STOFF’s impact will reach nationally and internationally as its participants will go on to conduct research that will have worldwide influence.

For more information, please visit [www.sto-online.org](http://www.sto-online.org) or send email to STOFF@sto-online.org